[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201810646VA - Abrasion-resistant opioid formulations - Google Patents

Abrasion-resistant opioid formulations

Info

Publication number
SG11201810646VA
SG11201810646VA SG11201810646VA SG11201810646VA SG11201810646VA SG 11201810646V A SG11201810646V A SG 11201810646VA SG 11201810646V A SG11201810646V A SG 11201810646VA SG 11201810646V A SG11201810646V A SG 11201810646VA SG 11201810646V A SG11201810646V A SG 11201810646VA
Authority
SG
Singapore
Prior art keywords
international
pct
dosage forms
cohesion
abuse
Prior art date
Application number
SG11201810646VA
Inventor
Jim Fai
Huai-Hung D Kao
Original Assignee
Relmada Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Relmada Therapeutics Inc filed Critical Relmada Therapeutics Inc
Publication of SG11201810646VA publication Critical patent/SG11201810646VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

WO 17 / 196 445 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 November 2017 (16.11.2017) WIPO I PCT omit IIl Hot 0 Oil El 100 Enna oimIE (10) International Publication Number WO 2017/196445 Al (51) International Patent Classification: A61K 31/00 (2006.01) A61K 31/485 (2006.01) (21) International Application Number: PCT/US2017/022012 (22) International Filing Date: 13 March 2017 (13.03.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/US2016/031796 11 May 2016 (11.05.2016) US (71) Applicant: RELMADA THERAPEUTICS, INC. [US/US]; 275 Madison Ave., Suite 702, New York, NY 10016 (US). (72) Inventors: FAI, Jim; 865 Willow Road, Franklin Square, NY 11010 (US). KAO, Huai-Hung D.; 137 Colony Lane, Syosset, NY 11791 (US). (74) Agent: COLBY, Gary D.; Dilworth Paxson LLP, 1500 Market Street, Suite 3500E, Philadelphia, PA 19102 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: ABRASION-RESISTANT OPIOID FORMULATIONS (57) : The disclosure relates to dosage forms which include one or more cohesion agents in amounts effective to reduce the likelihood and ease of extraction of an opioid agonist therefrom. The dosage forms exhibit improved resistance to abuse and lesser likelihood of accidental overdosing than similar dosage forms lacking a cohesion agent. Dosage forms including multiple cohesion agents capable of inhibiting or reducing extraction, abuse, or overdose over a broad range of temperatures are disclosed.
SG11201810646VA 2016-05-11 2017-03-13 Abrasion-resistant opioid formulations SG11201810646VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2016031796 2016-05-11
PCT/US2017/022012 WO2017196445A1 (en) 2016-05-11 2017-03-13 Abrasion-resistant opioid formulations

Publications (1)

Publication Number Publication Date
SG11201810646VA true SG11201810646VA (en) 2019-01-30

Family

ID=60267549

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810646VA SG11201810646VA (en) 2016-05-11 2017-03-13 Abrasion-resistant opioid formulations

Country Status (5)

Country Link
US (1) US20170326134A1 (en)
KR (1) KR20190028656A (en)
CN (1) CN109982690A (en)
SG (1) SG11201810646VA (en)
WO (1) WO2017196445A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020159901A1 (en) * 2019-01-31 2020-08-06 Relmada Therapeutics, Inc. Abrasion-resistant opioid formulations which resist abuse and include a sequestered opioid antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007054976A2 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
EP2744572B1 (en) * 2011-08-18 2017-12-13 BioDelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
WO2013119231A1 (en) * 2012-02-09 2013-08-15 Tris Pharma, Inc. Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings
CA2903200A1 (en) * 2013-03-15 2014-09-25 Mallinckrodt Llc Compositions comprising an opioid and an additional active pharmaceutical ingredient for rapid onset and extended duration of analgesia that may be administered without regard to food
CA2910865C (en) * 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose

Also Published As

Publication number Publication date
KR20190028656A (en) 2019-03-19
WO2017196445A1 (en) 2017-11-16
US20170326134A1 (en) 2017-11-16
CN109982690A (en) 2019-07-05

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201907427YA (en) Engineered transferrin receptor binding polypeptides
SG11201907023UA (en) Method of reducing neutropenia
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201804836RA (en) Treatment of fibrosis
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201805072PA (en) Nicotine powder delivery system
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201807549TA (en) Combination of a cxcr4 antagonist and an immune checkpoint inhibitor
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806853VA (en) Abstracted graphs from social relationship graph
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201807255YA (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201902988UA (en) Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof
SG11201808650QA (en) Methods of treating ocular conditions
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer